Motif Bio (LON:MTFB)‘s stock had its “buy” rating reissued by Peel Hunt in a research note issued on Tuesday.
Separately, Northland Securities reissued a “buy” rating on shares of Motif Bio in a research report on Thursday, September 20th.
Shares of LON:MTFB opened at GBX 24.43 ($0.32) on Tuesday. Motif Bio has a 1 year low of GBX 23.50 ($0.31) and a 1 year high of GBX 51.75 ($0.68).
Motif Bio Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Recommended Story: Do stock splits help investors?
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.